Gilead Sciences, Inc. (GILD) Stock
Gilead stock price chart
GILD stock quote & key statistics
Gilead annual financials
Income statement →| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $29.44B | $8.51B | $8.15 |
| FY2024 | $28.75B | $480.0M | $4.61 |
| FY2023 | $27.12B | $5.67B | $6.72 |
| FY2022 | $27.28B | $4.59B | $7.27 |
| FY2021 | $27.30B | $6.22B | $7.29 |
Fiscal year ending December 31. Source: company filings via EODHD.
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a pioneering biopharmaceutical company dedicated to discovering, developing, and commercializing medicines that address significant unmet medical needs worldwide. Based in Foster City, California, Gilead operates extensively across the United States, Europe, and other international markets. The company's diverse portfolio includes a range of groundbreaking treatments across multiple therapeutic areas.
Specializing in HIV/AIDS, Gilead offers a suite of products including Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla, which have transformed treatment paradigms for patients living with HIV/AIDS. In response to global health challenges, Gilead developed Veklury, an intravenous injection for the treatment of COVID-19, showcasing its commitment to addressing urgent medical crises.
Beyond infectious diseases, Gilead focuses on advancing therapies for liver diseases with products like Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The company also leads in hematology, oncology, and cell therapy with innovative treatments such as Yescarta, Tecartus, Trodelvy, and Zydelig. With extensive collaboration agreements with industry leaders and ongoing research initiatives, Gilead Sciences remains at the forefront of medical innovation, continually striving to improve patient outcomes and enhance global healthcare standards.
Gilead stock FAQ
What is the Gilead stock ticker symbol?
Gilead Sciences, Inc. trades on the NASDAQ under the ticker symbol GILD.
What sector and industry is Gilead in?
Gilead Sciences, Inc. is classified in the Healthcare sector, Drug Manufacturers - General industry.
How many employees does Gilead have?
Gilead Sciences, Inc. has about 17,000 full-time employees.
What were Gilead's revenue and earnings last fiscal year?
Gilead reported revenue of $29.44B and net income of $8.51B in fiscal 2025, with earnings per share of $8.15. Revenue grew 2.4% from the prior year.
Is Gilead in the Nasdaq-100?
Yes. Gilead Sciences, Inc. (GILD) is a component of the Nasdaq-100 index, which tracks the largest non-financial companies listed on the Nasdaq Stock Market.
Is Gilead in the S&P 500?
Yes. Gilead Sciences, Inc. (GILD) is a component of the S&P 500, the index of 500 leading U.S. companies widely used as a benchmark for the U.S. stock market.
Is Gilead in the Russell 1000?
Yes. Gilead Sciences, Inc. (GILD) is a component of the Russell 1000, which tracks roughly the 1,000 largest U.S. companies.
When did Gilead go public?
Gilead stock began trading on January 22, 1992.